期刊
CLINICAL AND TRANSLATIONAL MEDICINE
卷 7, 期 -, 页码 -出版社
SPRINGEROPEN
DOI: 10.1186/s40169-018-0211-8
关键词
Combination therapy; Glioblastoma multiforme; Glioblastoma stem cells; Targeted cancer therapy; Tumor microenvironment; Precision medicine; Chemotherapy; Tumor heterogeneity; Drug resistance; Radiotherapy; Immunotherapy; Clinical trials
Combination therapy is increasingly becoming the cornerstone of current day antitumor therapy. Glioblastoma multiforme is an aggressive brain tumor with a dismal median survival post diagnosis and a high rate of disease recurrence. The poor prognosis can be attributed to unique treatment limitations, which include the infiltrative nature of tumor cells, failure of anti-glioma drugs to cross the blood-brain barrier, tumor heterogeneity and the highly metastatic and angiogenic nature of the tumor making cells resistant to chemotherapy. Combination therapy approach is being developed against glioblastoma with new innovative combination drug regimens being tested in preclinical and clinical trials. In this review, we discuss the pathophysiology of glioblastoma, diagnostic markers, therapeutic targeting strategies, current treatment limitations, novel combination therapies in the context of current treatment options and the ongoing clinical trials for glioblastoma therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据